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Letters to the Editor
Sensory-motor axonal 
multineuropathy during 
etanercept therapy for 
rheumatoid arthritis
Sirs,
A 48-year-old woman had a 4-month his-
tory of polyarthritis without extra-articular 
features and particularly without skin le-
sions or neurologic impairment. Laboratory 
data showed RF at 203 IU/ml and elevated 
inﬂammatory markers while anti-CCP, 
ANA, ds-DNA, anti-ENA, APA, ANCA, 
serum complement and immunoglobulin 
levels were normal. Serology for recent in-
fection was negative. X-rays of the wrists, 
hands and feet showed juxta-articular os-
teoporosis. These features were consistent 
with highly active early RA, refractory to 
treatment including prednisone (12.5 mg/
die), NSAIDs and intraarticular injections 
of triamcinolone-acetonide. To achieve a 
rapid disease control with a monotherapy, 
etanercept (25 mg twice a week) without 
DMARDs was added to prednisone. About 
2 months after initiating therapy, polyar-
thritis was uncontrolled. In addition she 
reported a burning sensation in the feet and 
asymmetric paroxysmal dysesthesia involv-
ing the legs. Methotrexate (MTX) was add-
ed (15 mg weekly). The patient achieved 
a reduction of the swollen and tenderness 
joint count. However, dysestesia worsened, 
became chronic and symmetric in the lower 
limbs and spread asymmetrically in the 
upper limbs. Furthermore, the patient had 
developed severe motor distal deﬁcit par-
ticularly in the lower limbs. The electromy-
ograﬁc pattern was compatible with a sen-
sory-motor axonal multi-polyneuropathy. 
RF was raised at 445 IU/ml while serum 
complement, immunoglobulin levels, anti-
CCP, ANA, anti-dsDNA, anti-ENA, APA, 
ANCA, anti-ganglioside, anti-myelin pro-
tein and anti-cerebellum were normal. Anti-
PPD, anti-HIV, anti-Borrelia and serological 
hepatitis markers were negative. Investiga-
tions by PCR for HSV-1 and HSV-2 DNA, 
Cytomegalovirus DNA and Epstein-Barr 
virus DNA on blood were negative. Biopsy 
specimens were taken from the left sural 
nerve. Histological analysis showed axonal 
neuropathy without vascular inﬂamma-
tory inﬁltrate (Fig. 1). Etanercept and MTX 
were discontinued and prednisone was in-
creased (50 mg/die). Moreover, monthly 
plasma exchange followed by intravenous 
cyclophosphamide therapy (500mg/m2) and 
monthly therapy with high doses of intra-
venous Ig (400 mg/kg/die for 3 days) were 
given. Within 2 months the patient achieved 
a progressive improvement in the neuro-
logical features. Follow-up investigations 3 
months later showed further improvement 
in the neuropathy.
Our patient had a sensory-motor axonal 
multi-neuropathy suggesting vasculitic 
pathogenesis although histological analysis 
of nerve sample were characterised by ab-
sence of vascular inﬂammatory inﬁltrate. 
Some histological changes as pronounced 
multifocal myelinated ﬁber loss, more evi-
dent in centrofascicular area, typically are 
seen in ischemic damage. On the contrary, 
the electromyograﬁc and histological pat-
terns exclude a demyelinating neuropathy 
(Guillain-Barrè syndrome, etc.). We can-
not deﬁnitely exclude the development of 
rheumatoid vasculitis-associated multineu-
ropathy refractory to etanercept and MTX 
therapy. However, our patient did not have 
characteristics predisposing her to the de-
velopment of rheumatoid vasculitis, par-
ticularly nodularity and skin lesions. On the 
contrary, the temporal relationship between 
the onset of neuropathy and the initiation 
of etanercept therapy suggest that the drug 
may have contributed to trigger the neuro-
logical disease. 
While some reports have suggested that in-
hibition of TNF-α may be effective in rheu-
matoid vasculitis-associated mononeuritis 
(1-2), others have suggested that anti-TNF-
α can induce, in patients with RA, the devel-
opment of vasculitis (3-6) and particularly 
necrotizing vasculitis-associated sensory and 
motor neuropathy (7-8) or the progression 
of rheumatoid vasculitis-associated monon-
euritis multiplex (8). There are a number of 
possible drug-related mechanisms that may 
be involved, immunopathogenic mechanism 
or infectious complications. In our case the 
onset of multineuropathy was not associ-
ated with the production of autoantibodies 
and there were no signs of neurotoxic infec-
tive complications. Future studies should 
help to deﬁne the role of anti-TNF-α in the 
development of vasculitis and, particulary, 
in the development of axonal multineuropa-
thy. Undoubtedly, an inﬂammatory axonal 
neuropathy may develop in patients with 
RA treated with anti-TNF-α. This possibil-
ity demand careful neurological monitoring 
in such patients and prompts us to suggest, 
in agreement with Richette (9) and Guil-
levin (10), the use of anti-TNF-α only in 
patients with vasculitis refractory to ster-
oids and immunosuppressant agents.
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Fig. 1. A: Atrophy and axonal degeneration: a cross 
semithin section of sural nerve stained with toluidine 
bleu demonstrating myelinated ﬁber loss (residual den-
sity 1985/mm2) more evident in centrofascicular area 
(x200); B: Semi-thin section of sural nerve stained with 
toluidine bleu no showed vasculitic changes in large 
perineural vessel (x100).
